Intra-Cellular Therapies (ITCI) : Tuesdays money flow data in Intra-Cellular Therapies (ITCI) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $1.25 million, whereas, $0.37 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 3.39, in favor of the bulls. The total money flow into the stock was $0.88 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $0.81 million. The total value of block trades done on upticks was $0.81 million. Intra-Cellular Therapies (ITCI) fell $0.14 and traded at $40.56, down -0.34% for the day, over previous days close. On a weekly basis, the shares are 0.45% over the previous weeks close.
Also, Piper Jaffray initiates coverage on Intra-Cellular Therapies (NASDAQ:ITCI). The rating major has initiated the coverage with overweight rating on the shares. The Analysts at Piper Jaffray announces a current price target of $57 per share. The rating by the firm was issued on June 2, 2016.
Intra-Cellular Therapies, Inc. has lost 2.31% in the last five trading days and dropped 0.61% in the last 4 weeks. Intra-Cellular Therapies, Inc. is up 3.9% in the last 3-month period. Year-to-Date the stock performance stands at -23.8%.
Intra-Cellular Therapies (NASDAQ:ITCI): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $40.63 and $40.34 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $41.24. The buying momentum continued till the end and the stock did not give up its gains. It closed at $40.99, notching a gain of 0.71% for the day. The total traded volume was 447,171 . The stock had closed at $40.70 on the previous day.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Intra-Cellular Therapies, Inc., Riggs Rory B, had purchased 28,571 shares in a transaction dated on February 5, 2014. The transaction was executed at $17.5 per share with total amount equaling $499,993.
ITI Inc. is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc.